Accumulating evidence strongly suggests that RUNX1 promotes tumor aggressiveness in TNBC, while functioning as a tumor suppressor in ER+ breast cancer [18,20,21,22,23,24,25,26,27]. Here, RUNX1 is linked to breast cancer.